Director/PDMR Shareholding
16 December 2020 18:15 GMT
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announced that, on 16 December 2020, it was notified of transactions in the Company's Ordinary Shares of $0.25 each by certain Persons Discharging Managerial Responsibilities (PDMRs) of the Company as set out below.
| PDMR | Position | Nature of the transaction | Quantity | Price |
| Philip Broadley | Non-Executive Director | Purchase of Ordinary Shares | 1,310 | GB£76.25 |
| Nazneen Rahman | Non-Executive Director | Purchase of Ordinary Shares | 259 | GB£76.78 |
| Nazneen Rahman | Non-Executive Director | Purchase of Ordinary Shares | 258 | GB£76.79 |
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Philip Broadley | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
| b) | Nature of the transaction | Purchase of AstraZeneca PLC Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 16 December 2020 | ||||
| f) | Place of the transaction | XLON | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Nazneen Rahman | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
| b) | Nature of the transaction | Purchase of AstraZeneca PLC Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price | 517 GB£76.784 | ||||
| e) | Date of the transaction | 16 December 2020 | ||||
| f) | Place of the transaction | XLON | ||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.